| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
- | - | - | - | - | 2,948 | 0 | - |
Operating expense: | |||||||
Research & development | |||||||
6,438 | 11,848 | 21,686 | 18,869 | 12,381 | 6,432 | 3,994 | 5,907 |
General & administrative | |||||||
8,816 | 9,524 | 8,676 | 9,836 | 8,489 | 4,096 | 3,128 | 2,089 |
Total operating expenses | |||||||
15,254 | 21,372 | 30,362 | 28,705 | 20,870 | 10,528 | 7,122 | 7,996 |
Operating loss | |||||||
-15,254 | -21,372 | -30,362 | -28,705 | -20,870 | -7,580 | -7,122 | -7,996 |
Investment income | |||||||
262 | 436 | 259 | 193 | 144 | 24 | 4 | 20 |
Interest expense | |||||||
- | - | - | - | - | -857 | -861 | - |
Other income, net | |||||||
- | 207 | 139 | -14 | -651 | 5,071 | 67 | - |
Other income (Note 9) | |||||||
- | - | - | - | - | - | - | 6 |
Total other (income) expense, net | |||||||
262 | 643 | 398 | 179 | -507 | 4,238 | -790 | 26 |
Net Loss | |||||||
-14,992 | -20,729 | -29,964 | -28,526 | -21,377 | -3,342 | -7,912 | -7,970 |
Weighted Average Shares Outstanding, basic and diluted | |||||||
497 | 452 | 17,274 | 16,561 | 16,464 | 3,064 | 235 | 230 |
Foreign currency translation adjustment | |||||||
-2 | -1 | 6 | - | 0 | - | - | - |
Unrealized gain on available-for-sale investments | |||||||
- | 20 | -20 | 11 | -5 | -6 | -1 | -5 |
Comprehensive loss | |||||||
-14,994 | -20,710 | -29,978 | -28,515 | -21,382 | -3,348 | -7,913 | - |
Net loss | |||||||
-14,992 | -20,729 | -29,964 | -28,526 | -21,377 | -3,342 | -7,912 | -7,970 |
Accretion of convertible preferred stock to redemption value | |||||||
- | - | 6,747 | - | 0 | - | - | - |
Accretion of redeemable convertible preferred stock to redemption value | |||||||
- | - | - | - | - | 6,353 | 6,119 | 6,133 |
Net loss attributable to common stockholders | |||||||
- | - | -36,711 | -28,526 | -21,377 | -9,695 | -14,031 | -14,103 |
Net loss per share, basic and diluted | |||||||
-30.15 | -45.80 | -2.13 | -1.72 | -1.30 | -3.16 | -59.66 | -61.16 |
Allocated share-based compensation | |||||||
- | - | 3,227 | 3,343 | 2,164 | 459 | 155 | 110 |
Realized losses from forward foreign currency contracts | |||||||
- | - | - | - | -52 | 0 | 0 | - |
Unrealized gains (losses) from forward foreign currency contracts | |||||||
- | - | - | - | -537 | 0 | 0 | - |
Total | |||||||
- | - | - | - | -589 | 0 | 0 | - |
Comprehensive loss | |||||||
- | - | - | - | - | - | - | -7,975 |
Research and Development Expense [Member] | |||||||
Allocated share-based compensation | |||||||
- | - | 1,109 | 1,114 | - | - | - | - |
General and Administrative Expense [Member] | |||||||
Allocated share-based compensation | |||||||
- | - | 2,118 | 2,229 | - | - | - | - |